GSK’s two-speed pipeline strategy reflects a calculated balance between innovation and risk mitigation. By spreading early-stage bets across diverse partnerships—leveraging human data, genetics, and emerging modalities like RNA splicing—the company minimizes exposure to the high failure rates of early discovery. This approach aligns with broader industry trends toward externally sourced, data-driven target identification. However, the strategy also reveals a tension: while early-stage breadth re...